Humacyte, Inc. — Director's Dealing 2022

Dec 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-12-13

Reporting Person: Scheessele William John (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-13	Common Stock	P	5000	$3.09	Acquired	15525	Direct